Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Grifols SA

GRFS ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$7.88

▲ +0.64%

Market Cap $6.96B · Vol 130.95K

Key Metrics

P/E Ratio

10.19

FWD: 6.24

Market Cap

$6.96B

Mid Cap

Div Yield

2.35%

Dividend with no set frequency

EPS Growth

+25.48%

YoY

RSI (14)

53.33

Momentum

Beta

0.69

vs Market

52W High

$10.21

23.33% below

52W Low

$6.95

12.60% above

Volume

130.95K

Avg 122.61K

P/B

1.02

Price-to-book

ROE

8.92%

Return on equity

Free Float

100.00%

Public shares

Shariah Compliance8 STANDARDS

✗ Grifols SA (GRFS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GRFS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.77%

+0.25%

+5.66%

-8.65%

YTD

-15.58%

-17.70%

-15.94%

-46.38%

Financials & Valuation

TTM · Annual

Total Revenue	$8.84B
Net Income	$587.25M
Revenue Growth (YoY)	+1.61%
Gross Margin	38.00%
Operating Margin	16.63%
Net Profit Margin	6.65%
ROE	8.92%
ROA · ROIC	2.99% · 4.66%

P/E Ratio	10.19
Forward P/E (FY1)	6.24
PEG Ratio	0.08
P/S	0.75
P/B	1.02
P/FCF	9.03
EPS Growth	+25.48%
Outstanding Shares	687.55M

Technical Indicators

50-Day SMA	$7.67
200-Day SMA	$8.27
RSI (14)	53.33
Beta	0.69
52-Week High	$10.21
52-Week Low	$6.95

Volume Today	130.95K
Avg Daily Volume (30D)	122.61K
Relative Volume	1.07x
Volatility (10D)	18.10
Volatility (30D)	31.40
Free Float	100.00%

Analyst Consensus

BUY

Current Price $7.88

Mean Target $11.73

52W Low$6.95 52W High$10.21

Current

Target

$6.95 $10.21

Current Analyst target

+48.86% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V1HXJ9

ISINUS3984384087

CountrySpain

Sub-IndustryBiopharmaceuticals

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -1.00% CSL.AX CSL Ltd +0.95% 207940.KS Samsung Biologics Co Ltd -1.60% UCB.BR Ucb SA +0.09% BIIB Biogen Inc +0.83%

Company Profile

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.